This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Dendreon Announces Second Quarter 2013 Results

August 8, 2013--Dendreon Corporation (Nasdaq: DNDN) today reported results for the second quarter ended June 30, 2013. Net product revenue for the quarter was $73.3 million compared to $80.0 million for the quarter ended June 30, 2012, down 8.4% year over year and up 8.4% on a sequential basis.

Net loss in the second quarter of 2013 was $68.8 million, or $0.45 per share, compared to a net loss of $96.1 million, or $0.65 per share for the same period in 2012.

As of June 30, 2013, Dendreon had $280.6 million in cash, cash equivalents, and short-term and long-term investments, compared to $429.8 million as of December 31, 2012.

“During the second quarter, we made progress turning around what was a challenging first quarter, with solid growth in large accounts where we are focused,” said John H. Johnson, chairman, president and chief executive officer of Dendreon. “Urology led the way, with 37% quarter-over-quarter growth, and our highest-ever sales in this segment. We have received supportive feedback from physicians, patients and key opinion leaders about PROVENGE, and remain focused on improving utilization through our direct-to-consumer advertising campaign, which is generating positive early indicators.”

Second Quarter Highlights:
  • Received a positive opinion from the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) recommending that PROVENGE ® (sipuleucel-T) be granted marketing authorization in the European Union (EU)
  • Continued new physician interest in PROVENGE:
    • Added 42 net new accounts in the second quarter
  • Continued to make traction with direct-to-consumer (DTC) advertising campaign:
    • Addresses significant need for patient education and awareness
    • First national television commercial aired on March 7
    • Patients contacting Dendreon directly for more information, resulting in a significant increase in call center and relationship marketing activity
    • Seeing registrations to relationship marketing program increase significantly when ad is on the air and registrations are converting to enrollments faster than expected
  • Continued focus on expanding clinical data
    • Completed enrollment of PROVENGE and ADT (androgen deprivation therapy) sequencing study; presented initial data at ASCO-GU and expect to present additional data in 2013
    • Completed enrollment of PROVENGE and Zytiga ® (abiraterone acetate) sequencing study; presented initial data at ASCO-GU and expect to present additional data in 2013
    • Finalized trial design and named steering committee for Phase II trial for sequencing PROVENGE with Xtandi ® (enzalutamide) and expect to begin enrolling patients in the fourth quarter of 2013
    • Supporting 19 novel investigator initiated trials (IITs) to advance understanding of immunotherapy and the treatment of advanced prostate cancer
    • Intensifying efforts in the biomarker discovery program and identified some potential pre-treatment biomarkers in a preliminary data set
    • Initiated an early detection study named PREDICT that will image castrate-resistant patients without known metastatic disease. Data from this study may help physicians better identify mCRPC patients early in the disease state.
    • Continuing to advance pipeline including DN24-02, Dendreon’s investigational autologous cell immunotherapy based on the same platform as PROVENGE but targeting the tumor antigen HER2/neu

The Company noted that urology sales have grown to its highest level since launch and sales trends in large accounts have rebounded since Q1 of 2013. The number of large accounts, defined as having an annual run rate of more than $1 million in sales, has grown to its highest level post competitive entries. However, based upon current enrollment trends in July and August, Dendreon does not expect to see enough of a sales increase in the second half of the year to meet its goal of growing PROVENGE year over year. The Company noted that the competitive environment remains largely unchanged from the first quarter.

1 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 17,813.39 +1.20 0.01%
S&P 500 2,088.87 -0.27 -0.01%
NASDAQ 5,116.1430 +13.3350 0.26%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs